Genentech and Biogen Idec, Inc. (Massachusetts) Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Copenhagen, Denmark; May 17, 2013 – Genmab A/S (OMX: GEN) announced today that Genentech and Biogen Idec have filed for a re-hearing en banc (i.e. before all judges of the court) in the appeal case, where the U.S. Court of Appeals for the Federal Circuit recently upheld the U.S. District Court's judgment in favor of GlaxoSmithKline (GSK). The appeal case relates to a patent infringement case involving Arzerra® brought against GSK by Genentech and Biogen Idec.
Help employers find you! Check out all the jobs and post your resume.
Copenhagen, Denmark; May 17, 2013 – Genmab A/S (OMX: GEN) announced today that Genentech and Biogen Idec have filed for a re-hearing en banc (i.e. before all judges of the court) in the appeal case, where the U.S. Court of Appeals for the Federal Circuit recently upheld the U.S. District Court's judgment in favor of GlaxoSmithKline (GSK). The appeal case relates to a patent infringement case involving Arzerra® brought against GSK by Genentech and Biogen Idec.
Help employers find you! Check out all the jobs and post your resume.